Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impacts quality of life and often ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3b/4 clinical study ...

University of Queensland (UQ) researchers have become the first in the world to successfully grow fully functioning human ...

Patients with moderate to severe atopic dermatitis treated with amlitelimab showed both clinical and biomarker improvements, including in patients who withdrew from treatment, according to phase ...

Atopic dermatitis, the most common form of eczema, is a widespread skin condition known for causing dry, itchy and inflamed skin. It affects 15% to 20% of children and 8% to 10% of adults.

The use of topical corticosteroids to treat atopic dermatitis in infants also may help prevent hen’s egg allergy, but it may inhibit the baby’s growth as well, according to a study published ...

Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with rough, scaly patches. It affects up to 30% of children and 10% of adults, with about 60% of cases starting before age 1.

Nektar Therapeutics said a study of rezpegaldesleukin showed that the atopic dermatitis treatment met key endpoints. The clinical-stage biotechnology company said data from the 16-week induction ...

EP: 12. EP: 13. EP: 14. Casey Butrus, PharmD: Dr Keegan, explain the treatment landscape for atopic dermatitis [AD] and the therapeutic categories and options we have available for our patients.

Dupilumab, an anti-IL-4 and anti-IL-13 monoclonal antibody, is indicated in Europe for the treatment of moderate to severe atopic dermatitis that requires systemic treatment.

Biologics for the Treatment of Adolescent Atopic Dermatitis : Episode 5 Video May 29, 2019 ...

University of Zurich. "New potential approach to treat atopic dermatitis." ScienceDaily. ScienceDaily, 18 March 2019. <www.sciencedaily.com / releases / 2019 / 03 / 190318111958.htm>.